Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial
Richard Lafayette, Jens Kristensen, Andrew Stone, Jürgen Floege, Vladimı́r Tesař, Hernán Trimarchi, Hong Zhang, Necmi Eren, Alexander Paliege, Heather N. Reich, Brad H. Rovin, Jonathan Barratt
Topics & Concepts
MedicineProteinuriaClinical endpointRenal functionInternal medicinePlaceboNephropathyKidney diseaseClinical trialGastroenterologyKidneyPathologyEndocrinologyDiabetes mellitusAlternative medicineRenal Diseases and GlomerulopathiesChronic Kidney Disease and DiabetesNephrotoxicity and Medicinal Plants